140 related articles for article (PubMed ID: 18676734)
1. Moving toward individualized cancer therapies.
Tonon G; Anderson KC
Clin Cancer Res; 2008 Aug; 14(15):4682-4. PubMed ID: 18676734
[TBL] [Abstract][Full Text] [Related]
2. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
Glinsky GV
J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
[TBL] [Abstract][Full Text] [Related]
3. Cancer biology: signatures guide drug choice.
Downward J
Nature; 2006 Jan; 439(7074):274-5. PubMed ID: 16421553
[No Abstract] [Full Text] [Related]
4. Cancer pharmacogenetics.
Marsh S
Methods Mol Biol; 2008; 448():437-46. PubMed ID: 18370241
[TBL] [Abstract][Full Text] [Related]
5. Enabling personalized cancer medicine through analysis of gene-expression patterns.
van't Veer LJ; Bernards R
Nature; 2008 Apr; 452(7187):564-70. PubMed ID: 18385730
[TBL] [Abstract][Full Text] [Related]
6. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer.
De Toni EN; Thieme SE; Herbst A; Behrens A; Stieber P; Jung A; Blum H; Göke B; Kolligs FT
Clin Cancer Res; 2008 Aug; 14(15):4713-8. PubMed ID: 18676739
[TBL] [Abstract][Full Text] [Related]
7. Genes versus cancer.
Lewis R
Nature; 2007 Apr; 446(7137):826-7. PubMed ID: 17460827
[No Abstract] [Full Text] [Related]
8. Genomic medicines for oncology: early lessons.
Simons JW
J Med Assoc Ga; 2003; 92(1):35-8. PubMed ID: 12743904
[No Abstract] [Full Text] [Related]
9. Genetic testing in cancer therapeutics.
Ezzeldin HH; Diasio RB
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4137-41. PubMed ID: 16857783
[No Abstract] [Full Text] [Related]
10. Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Dawood S
Cancer Invest; 2009 Oct; 27(8):809-15. PubMed ID: 19731103
[No Abstract] [Full Text] [Related]
11. Somatic pharmacogenomics in cancer.
Ikediobi ON
Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
[TBL] [Abstract][Full Text] [Related]
12. Obesity and cancer treatment: weighing the evidence.
Griggs JJ; Sabel MS
J Clin Oncol; 2008 Sep; 26(25):4060-2. PubMed ID: 18757320
[No Abstract] [Full Text] [Related]
13. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis and non-apoptotic deaths in cancer development and treatment response.
de Bruin EC; Medema JP
Cancer Treat Rev; 2008 Dec; 34(8):737-49. PubMed ID: 18722718
[TBL] [Abstract][Full Text] [Related]
15. Childhood ALL researchers focus on high-risk patients.
Friedrich MJ
J Natl Cancer Inst; 2009 May; 101(10):702-4. PubMed ID: 19436027
[No Abstract] [Full Text] [Related]
16. The person in personalised medicine.
Doz F; Marvanne P; Fagot-Largeault A
Eur J Cancer; 2013 Mar; 49(5):1159-60. PubMed ID: 23265710
[No Abstract] [Full Text] [Related]
17. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
18. A checklist for evaluating reports of expression profiling for treatment selection.
Simon R
Clin Adv Hematol Oncol; 2006 Mar; 4(3):219-24. PubMed ID: 16728933
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives.
Nannini M; Pantaleo MA; Maleddu A; Astolfi A; Formica S; Biasco G
Cancer Treat Rev; 2009 May; 35(3):201-9. PubMed ID: 19081199
[TBL] [Abstract][Full Text] [Related]
20. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
